|
1
|
Chia KS, Reilly M, Tan CS, Lee J, Pawitan
Y, Adami HO, Hall P and Mow B: Profound changes in breast cancer
incidence may reflect changes into a Westernized lifestyle: A
comparative population-based study in Singapore and Sweden. Int J
Cancer. 113:302–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leung GM, Thach TQ, Lam TH, Hedley AJ, Foo
W, Fielding R, Yip PS, Lau EM and Wong CM: Trends in breast cancer
incidence in Hong Kong between 1973 and 1999: An age-period-cohort
analysis. Br J Cancer. 87:982–988. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung H, Ren J, Li J, Pfeiffer RM, Wang Y,
Guida JL, Fang Y, Shi J, Zhang K, Li N, et al: Breast cancer risk
factors and mammographic density among high-risk women in urban
China. NPJ Breast Cancer. 4:32018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moss EG: MicroRNAs: Hidden in the genome.
Curr Biol. 12:R138–R140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lv C, Li F, Li X, Tian Y, Zhang Y, Sheng
X, Song Y, Meng Q, Yuan S, Luan L, et al: miR-31 promotes mammary
stem cell expansion and breast tumorigenesis by suppressing Wnt
signaling antagonists. Nat Commun. 8:10362017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kojima S, Chiyomaru T, Kawakami K, Yoshino
H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M and
Seki N: Tumour suppressors miR-1 and miR-133a target the oncogenic
function of purine nucleoside phosphorylase (PNP) in prostate
cancer. Br J Cancer. 106:405–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dong Y, Zhao J, Wu CW, Zhang L, Liu X,
Kang W, Leung WW, Zhang N, Chan FK, Sung JJ, et al: Tumor
suppressor functions of miR-133a in colorectal cancer. Mol Cancer
Res. 11:1051–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo J, Xia B, Meng F and Lou G: miR-133a
suppresses ovarian cancer cell proliferation by directly targeting
insulin-like growth factor 1 receptor. Tumour Biol. 35:1557–1564.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao L, Li SH, Tian YX, Zhu QQ, Chen G,
Pang YY and Hu XH: Role of downregulated miR-133a-3p expression in
bladder cancer: A bioinformatics study. OncoTargets Ther.
10:3667–3683. 2017. View Article : Google Scholar
|
|
10
|
Zhou GQ, Han F, Shi ZL, Yu L, Li XF, Yu C,
Shen CL, Wan DW, Zhu XG, Li R and He SB: miR-133a-3p targets
SUMO-specific protease 1 to inhibit cell proliferation and cell
cycle progress in colorectal cancer. Oncol Res. 26:795–800. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CC, Hardy DB and Mendelson CR:
Progesterone receptor inhibits proliferation of human breast cancer
cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1). J Biol
Chem. 286:43091–43102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou YX, Zhang H and Peng C: Puerarin: A
review of pharmacological effects. Phytother Res. 28:961–975. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu X, Li S, Li Y, Cheng B, Tan B and Wang
G: Puerarin inhibits proliferation and induces apoptosis by
upregulation of miR-16 in bladder cancer cell line T24. Oncol Res.
26:1227–1234. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng X, Feng Q, Zhao F, Sun C, Zhou T,
Yang J and Zhan X: Puerarin inhibits TRPM3/miR-204 to promote
MC3T3-E1 cells proliferation, differentiation and mineralization.
Phytother Res. 32:996–1003. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yin M, Yuan Y, Cui Y, Hong X, Luo H, Hu X,
Tang M, Hescheler J and Xi J: Puerarin suppresses the self-renewal
of murine embryonic stem cells by inhibition of REST-miR-21
regulatory pathway. Cell Physiol Biochem. 37:527–536. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang WG, Liu XF, Meng KW and Hu SY:
Puerarin inhibits growth and induces apoptosis in SMMC-7721
hepatocellular carcinoma cells. Mol Med Rep. 10:2752–2758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang H, Zhang J, Wang B, Liu M, Zhao J,
Yang M and Li Y: Puerarin inhibits M2 polarization and metastasis
of tumor-associated macrophages from NSCLC xenograft model via
inactivating MEK/ERK 1/2 pathway. Int J Oncol. 50:545–554. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Donepudi MS, Kondapalli K, Amos SJ and
Venkanteshan P: Breast cancer statistics and markers. J Cancer Res
Ther. 10:506–511. 2014.PubMed/NCBI
|
|
20
|
Ciriello G, Gatza ML, Beck AH, Wilkerson
MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et
al: Comprehensive molecular portraits of invasive lobular breast
cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Alkabban FM and Ferguson T: Cancer,
Breast. StatPearls Publishing; Treasure Island, FL: 2018
|
|
23
|
Xu SY, Huang X and Cheong KL: Recent
advances in marine algae polysaccharides: Isolation, structure, and
activities. Mar Drugs. 15:E3882017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du J, Sun Y, Lu YY, Lau E, Zhao M, Zhou QM
and Su SB: Berberine and evodiamine act synergistically against
human breast cancer MCF-7 cells by inducing cell cycle arrest and
apoptosis. Anticancer Res. 37:6141–6151. 2017.PubMed/NCBI
|
|
25
|
Tsai YT, Lai JN, Lo PC, Chen CN and Lin
JG: Prescription of Chinese herbal products is associated with a
decreased risk of invasive breast cancer. Medicine (Baltimore).
96:e79182017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang K, Chen H, Tang K, Guan W, Zhou H,
Guo X, Chen Z, Ye Z and Xu H: Puerarin inhibits bladder cancer cell
proliferation through the mTOR/p70S6K signaling pathway. Oncol
Lett. 15:167–174. 2018.PubMed/NCBI
|
|
27
|
Sui Y, Zhang X, Yang H, Wei W and Wang M:
MicroRNA-133a acts as a tumour suppressor in breast cancer through
targeting LASP1. Oncol Rep. 39:473–482. 2018.PubMed/NCBI
|
|
28
|
Kesarwani M, Kincaid Z, Gomaa A, Huber E,
Rohrabaugh S, Siddiqui Z, Bouso MF, Latif T, Xu M, Komurov K, et
al: Targeting c-FOS and DUSP1 abrogates intrinsic resistance to
tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nat
Med. 23:472–482. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nettersheim D, Jostes S, Fabry M, Honecker
F, Schumacher V, Kirfel J, Kristiansen G and Schorle H: A signaling
cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and
affects the cell cycle of germ cell cancers after romidepsin
treatment. Oncotarget. 7:74931–74946. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rukov JL and Shomron N: MicroRNA
pharmacogenomics: Post-transcriptional regulation of drug response.
Trends Mol Med. 17:412–423. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qian YY, Liu ZS, Zhang Z, Levenson AS and
Li K: Pterostilbene increases PTEN expression through the targeted
downregulation of microRNA-19a in hepatocellular carcinoma. Mol Med
Rep. 17:5193–5201. 2018.PubMed/NCBI
|
|
32
|
Wei HY, Zhang YJ and Zhao SZ: Puerarin
regulates neovascular glaucoma through pigment epitheliumderived
growth factorinduced NFκB signaling pathway. Mol Med Rep.
17:7866–7874. 2018.PubMed/NCBI
|
|
33
|
Xiao M, Li J, Li W, Wang Y, Wu F, Xi Y,
Zhang L, Ding C, Luo H, Li Y, et al: MicroRNAs activate gene
transcription epigenetically as an enhancer trigger. RNA Biol.
14:1326–1334. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Low HB and Zhang Y: Regulatory roles of
MAPK phosphatases in cancer. Immune Netw. 16:85–98. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang B, Li SL, Xie HL, Fan JW, Gu CW,
Kang C and Teng MJ: Effects of silencing the DUSP1 gene using
lentiviral vector-mediated siRNA on the release of proinflammatory
cytokines through regulation of the MAPK signaling pathway in mice
with acute pancreatitis. Int J Mol Med. 41:2213–2224.
2018.PubMed/NCBI
|
